276 related articles for article (PubMed ID: 28315938)
21. Expression of p16 and pRB in invasive breast cancer.
Shin E; Jung WH; Koo JS
Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas.
Pekmezci M; Szpaderska A; Osipo C; Erşahin Ç
Int J Surg Pathol; 2013 Apr; 21(2):126-32. PubMed ID: 23204031
[TBL] [Abstract][Full Text] [Related]
23. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
Desouki MM; Atta IS; Wolff DJ; Self SE
Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
[TBL] [Abstract][Full Text] [Related]
24. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
[TBL] [Abstract][Full Text] [Related]
25. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
Arafah M
Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
[TBL] [Abstract][Full Text] [Related]
26. Lymphatic vascularization in primary breast cancer: HER2 overexpressing tumors contain more lymphatics than steroid receptor positive, triple-positive and triple negative breast carcinomas.
Popovska S; Ivanov I
Turk Patoloji Derg; 2014; 30(2):124-32. PubMed ID: 24782302
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
[TBL] [Abstract][Full Text] [Related]
28. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
29. Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma.
East EG; Pang JC; Kidwell KM; Jorns JM
Am J Clin Pathol; 2015 Dec; 144(6):952-9. PubMed ID: 26573003
[TBL] [Abstract][Full Text] [Related]
30. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia.
Lin CH; Liau JY; Lu YS; Huang CS; Lee WC; Kuo KT; Shen YC; Kuo SH; Lan C; Liu JM; Kuo WH; Chang KJ; Cheng AL
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1807-14. PubMed ID: 19505913
[TBL] [Abstract][Full Text] [Related]
31. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type.
Monhollen L; Morrison C; Ademuyiwa FO; Chandrasekhar R; Khoury T
Histopathology; 2012 Sep; 61(3):365-77. PubMed ID: 22486370
[TBL] [Abstract][Full Text] [Related]
32. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
33. EGFR expression and activation are common in HER2 positive and triple-negative breast tumours.
Koletsa T; Kotoula V; Karayannopoulou G; Nenopoulou E; Karkavelas G; Papadimitriou CS; Kostopoulos I
Histol Histopathol; 2010 Sep; 25(9):1171-9. PubMed ID: 20607659
[TBL] [Abstract][Full Text] [Related]
34. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
35. Intraocular Metastases Secondary to Breast Carcinoma Correlates With Upregulation of Estrogen and Progesterone Receptor Expression in the Primary Tumor.
Parrozzani R; Frizziero L; Testi I; Miglionico G; Perrini P; Pulze S; Pilotto E; Midena E
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):3944-8. PubMed ID: 27479811
[TBL] [Abstract][Full Text] [Related]
36. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
37. [Tryptase- and chymase-positive mast cells as possible prognostic factor in patients with Hodgkin's lymphoma].
Rygoł B; Kyrcz-Krzemień S; Pajiak J; Konicki P; Kowai E; Gasińska T
Pol Arch Med Wewn; 2007; 117(1-2):27-32. PubMed ID: 17642203
[TBL] [Abstract][Full Text] [Related]
38. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
39. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia.
Satti MB
Histopathology; 2011 Sep; 59(3):537-42. PubMed ID: 21668473
[TBL] [Abstract][Full Text] [Related]
40. Mast cells expressing chymase but not tryptase can be derived by culturing human progenitors in conditioned medium obtained from a human mastocytosis cell strain with c-kit ligand.
Li L; Meng XW; Krilis SA
J Immunol; 1996 Jun; 156(12):4839-44. PubMed ID: 8648132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
